Related Experiment Video
Updated: Jul 20, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
CD200 genotype is associated with clinical outcome of patients with multiple myeloma
Yolanda Gonzalez-Montes1, Gemma Osca-Gelis2,3,4, Rocío Rodriguez-Romanos1
1Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Universitat de Girona, Girona, Spain.
Abstract:
Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events.
Insights
The CD200 rs1131199 GG genotype is linked to poorer survival in multiple myeloma (MM) patients, particularly those not undergoing stem cell transplant. This genotype may increase non-relapse mortality, often due to infections.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Immune dysfunction is central to multiple myeloma (MM).
- Cancer cells evade immune surveillance via immune checkpoints.
- Data on immune checkpoints predicting MM progression are limited.
Purpose of the Study:
- To investigate the clinical impact of CD200 gene polymorphisms (rs1131199 and rs2272022) in newly diagnosed MM patients.
- To assess the role of CD200 genotype in myeloma control and immune escape.
- To evaluate the predictive value of CD200 genotype on patient survival.
Main Methods:
- Retrospective analysis of 291 newly diagnosed MM patients.
- Genotyping for CD200 polymorphisms (rs1131199 and rs2272022).
- Survival analysis including overall survival (OS) and multivariate analysis.
Main Results:
- Patients with the CD200 rs1131199 GG genotype had significantly lower median OS (67.8 months) compared to CC+CG genotypes (94.4 months; p=0.022).
- This association remained significant in multivariate analysis.
- In patients not receiving autologous stem cell transplant (auto-SCT), the rs1131199 GG genotype was linked to increased non-relapse mortality (p=0.02), primarily due to infections.
Conclusions:
- The CD200 rs1131199 genotype is a potential prognostic marker in MM.
- The rs1131199 GG genotype may predict poorer outcomes, especially in patients not undergoing auto-SCT.
- CD200 genotype may influence non-relapse mortality through mechanisms like infection susceptibility.
More Related Videos
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
